Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy EyeGate Pharmaceuticals stock

Learn how to easily invest in EyeGate Pharmaceuticals stock.

EyeGate Pharmaceuticals Inc is a healthcare business based in the US. EyeGate Pharmaceuticals shares (EYEG) are listed on the NASDAQ and all prices are listed in US Dollars. EyeGate Pharmaceuticals employs 14 staff and has a trailing 12-month revenue of around $12,059.

How to buy shares in EyeGate Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – EYEG – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

EyeGate Pharmaceuticals stock price (NASDAQ: EYEG)

Use our graph to track the performance of EYEG stocks over time.

EyeGate Pharmaceuticals shares at a glance

Information last updated 2022-03-06.
Latest market close$1.00
52-week range$0.80 - $2.34
50-day moving average $1.86
200-day moving average $3.47
Wall St. target price$11.83
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.63

Buy EyeGate Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$0
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Public
Stocks, ETFs, Cryptocurrency
$0
$0
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
Tradier
Stocks, Options, ETFs
$0
$0
N/A
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy EyeGate Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

EyeGate Pharmaceuticals price performance over time

Historical closes compared with the close of $1 from 2022-01-07

1 week (2022-09-20) N/A
1 month (2022-08-28) N/A
3 months (2022-06-27) N/A
6 months (2022-03-28) N/A
1 year (2021-10-01) -50.50%
2 years (2020-10-01) -74.68%
3 years (2019-10-01) 2.96
5 years (2017-09-29) 1.17

EyeGate Pharmaceuticals financials

Revenue TTM $12,059
Gross profit TTM $-3,553,986
Return on assets TTM -40.35%
Return on equity TTM -103.8%
Profit margin 0%
Book value $1.47
Market capitalisation $24.7 million

TTM: trailing 12 months

EyeGate Pharmaceuticals share dividends

We're not expecting EyeGate Pharmaceuticals to pay a dividend over the next 12 months.

Have EyeGate Pharmaceuticals's shares ever split?

EyeGate Pharmaceuticals's shares were split on a 1:15 basis on 29 August 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your EyeGate Pharmaceuticals shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for EyeGate Pharmaceuticals shares which in turn could have impacted EyeGate Pharmaceuticals's share price.

EyeGate Pharmaceuticals share price volatility

Over the last 12 months, EyeGate Pharmaceuticals's shares have ranged in value from as little as $0.8002 up to $2.34. A popular way to gauge a stock's volatility is its "beta".

EYEG.US volatility(beta: 0.8)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while EyeGate Pharmaceuticals's is 0.7974. This would suggest that EyeGate Pharmaceuticals's shares are less volatile than average (for this exchange).

EyeGate Pharmaceuticals overview

EyeGate Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company, focuses on developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system in the United States. It develops PP-001, a clinical stage dihydroorotate dehydrogenase inhibitor that has been developed in two clinical-stage ophthalmic formulations, consisting of PaniJect that is in Phase Ia/IIb clinical trial for multiple diseases that affect the posterior region of the eye, including non-infectious posterior uveitis and diabetic macular edema; and PaniDrop, which is in Phase I safety study for multiple diseases that affect the ocular surface and anterior region of the eye, comprising of allergic conjunctivitis, viral conjunctivitis, and dry eye disease. The company also develops ocular bandage gel, a modified form of the natural polymer hyaluronic acid for corneal wound repair, and punctate epitheliopathies with a focus on dry eye. The company has license agreements with BioTime, Inc. Eyegate Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Waltham, Massachusetts.

Frequently asked questions

What percentage of EyeGate Pharmaceuticals is owned by insiders or institutions?
Currently 12.015% of EyeGate Pharmaceuticals shares are held by insiders and 24.577% by institutions.
How many people work for EyeGate Pharmaceuticals?
Latest data suggests 14 work at EyeGate Pharmaceuticals.
When does the fiscal year end for EyeGate Pharmaceuticals?
EyeGate Pharmaceuticals's fiscal year ends in December.
Where is EyeGate Pharmaceuticals based?
EyeGate Pharmaceuticals's address is: 271 Waverley Oaks Road, Waltham, MA, United States, 02452
What is EyeGate Pharmaceuticals's ISIN number?
EyeGate Pharmaceuticals's international securities identification number is: US49721T1016
What is EyeGate Pharmaceuticals's CUSIP number?
EyeGate Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 30233M107

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site